Eucure Biopharma, a wholly owned subsidiary of Biocytogen, is committed to clinical development for Biocytogen’s R&D pipelines. Leveraging a seasoned clinical development team with extensive experience in both domestic and global drug development, Eucure Biopharma is focused on developing innovative antibody drugs to address the needs of patients both in China and abroad. Since its establishment in October 2019, the company has built a pipeline of over 10 Biocytogen-developed targets.
The Eucure clinical development team is composed of experts in pharmacy (CMC), pharmacology and toxicology, regulatory affairs, clinical medicine, clinical operations, data management and statistical analysis, drug safety, and pharmacovigilance. Our core competitiveness lies in our global strategic vision and international clinical development experience, our ability to design clinical study protocols for various types of studies at different stages, our expertise in international regulatory affairs (FDA, TGA, and NMPA), and our efficient and effective clinical operation execution and collaboration with KOL/PI.
Aligned with Biocytogen’s strategic planning, we have established bases in Beijing, Shanghai, and the United States.
For more information, please visit https://www.eucure.com/en/index.